In surveillance of HPV+ anal cancer, inconclusive exam and imaging results are common, especially for patients in early surveillance. In a study of 233 patients, 42% received at least one clinically indeterminate finding (CIF) during follow-up. 46% of these CIFs were from exams and 54% were from imaging. [1]  Join us for an industry expert theater at the ASTRO Annual Meeting, happening now, to see how clinicians can gain new insight into equivocal findings:  Leveraging ctHPVDNA Testing to See Through Ambiguous Findings in Anal Cancer Speaker: Rafi Kabarriti, MD, Radiation Oncology, Albert Einstein College of Medicine Monday, September 28, 2026 | Time: 3:00–4:00 p.m. Location: Blue Theater, Exhibit Hall Register for this event: bit.ly/3TwOS26    #ASTRO26 #ctDNA #ctHPVDNA #LiquidBiopsy #CancerSurveillance #Oncology #HPV #HPVcancer #AnalCancer #ASCC #RadiationOncology #NavDx #CareDx ASTRO Industry Theater Information: bit.ly/454njzJ 1. doi.org/10.3390/cancers18010….

The NavDx® team is attending the ASTRO Annual Meeting beginning this weekend in Boston! Visit our team at Booth #1719 throughout the conference.   And, if traditional options for resolving clinically indeterminate findings in HPV+ anal cancer don’t give you the answers you need with the confidence you demand, join us for an industry expert theater:  Leveraging ctHPVDNA Testing to See Through Ambiguous Findings in Anal Cancer Speaker: Rafi Kabarriti, MD, Radiation Oncology, Albert Einstein College of Medicine Monday, September 28, 2026 | Time: 3:00–4:00 p.m. Location: Blue Theater, Exhibit Hall Register for this event: bit.ly/3TwOS26   #ASTRO26 #ctDNA #ctHPVDNA #LiquidBiopsy #CancerSurveillance #Oncology #HPV #HPVcancer #AnalCancer #ASCC #RadiationOncology #NavDx #CareDx ASTRO Industry Theater Information: bit.ly/454njzJ

The NavDx® team is looking forward to connecting with the head and neck cancer community at #AHNS2026 and advancing conversation around the evolving role of TTMV-HPV DNA and NavDx testing in the management of HPV+ oropharyngeal cancer. On SUNDAY, join us for a lunch symposium: Evolving into Consensus: ctHPVDNA in Clinical Practice           July 19, 2026 | 12:15–1:45 PM Room 258C Leading clinicians and investigators will share emerging consensus, clinical experience, and real-world insights on incorporating NavDx testing into patient management. Register now for the Symposium: bit.ly/4wD7o70  On TUESDAY, don't miss the proffered paper presentation: TTMV Score at Molecular Recurrence Predicts Response to Salvage Therapy in HPV-driven Cancers (Abstract #153892) Jamie Jabalee, PhD July 21, 2026 | 3:30–5:00 PM Room 259AB And, visit us throughout the meeting at Booth #612 to learn how the NavDx test continues to support clinicians with actionable insight for HPV-driven cancers. Register now for the AHNS 12th International Conference ahns2026.org/   #AHNS2026 #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerDiagnostics #PrecisionOncology #CancerSurveillance #Oncology #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OropharyngealCancer #OPSCC #RadiationOncology #MedicalOncology #ENT #NavDx #CareDx

We are excited to sponsor “Boston Tour: By Land and By Sea” for attendees of the Head & Neck Cancer Alliance’s 2026 Survivorship Symposium. Join us after the Symposium for a guided evening tour that brings the city to life through a 1-hour narrated trolley tour followed by a 1-hour scenic riverboat cruise.  Learn more or register for the Survivorship Symposium: bit.ly/4aPUxpJ #Survivorship #NavDx #CareDx #CancerSurvivor #CancerThriver #CancerSupport #StrongerTogether #Caregivers #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC

NavDx® is pleased to be a sponsor of the 2026 Head and Neck Cancer Survivorship Symposium, presented by @hncalliance and @AHNSinfo on July 18 beginning at 8:30am Eastern. Life after cancer can be a difficult time, especially for those recovering from head and neck cancer. This event brings together survivors, caregivers, patients in treatment, and healthcare providers to hear from medical experts, learn practical strategies for life after treatment, and connect with others who understand what patients are going through. For more information or to register (attend online or in-person), visit bit.ly/4aPUxpJ. #Survivorship #HPV #HPVcancer #HeadAndNeckCancer #HNcancer #CancerSurvivor #CancerThriver #CancerSupport #StrongerTogether #Caregivers #NavDx #CareDx

Join us at the American Head and Neck Society’s 12th International Conference to hear a discussion of the landmark recommendations from the California Head and Neck Consortium on the use of ctHPVDNA testing in the management of HPV-driven OPSCC (bit.ly/4f8i72k).  Evolving into Consensus: ctHPVDNA in Clinical Practice Sunday, July 19th | 12:15pm -1:45pm Menino Convention and Exhibit Center Room: 258C Register today for the Symposium: bit.ly/4wD7o70  #AHNS2026 #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OropharyngealCancer #OPSCC #RadiationOncology #MedicalOncology #ENT #NavDx #CareDx

The California Head and Neck Consortium (CHNC) recently published landmark recommendations on the use of circulating tumor HPV DNA (ctHPVDNA) assays for post-treatment surveillance of HPV+ oropharyngeal cancer.  Thirty-three multidisciplinary experts from 15 institutions established: ✔ ctHPVDNA offers greater specificity and sensitivity and shortens time to detection of recurrence ✔ Serial testing is recommended over single post-treatment time-point testing ✔ Serial testing is recommended in years 1–5, alongside routine surveillance visits ✔ Detection of ctHPVDNA without clinical confirmation of recurrence should prompt more frequent imaging  Experts from CHNC will do a deep dive into these insights at a lunch symposium at the American Head and Neck Society’s 12th International Conference. Join us Sunday, July 19th at 12:15pm in Room 258C at AHNS 2026. We hope to see you there! #AHNS2026 #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OropharyngealCancer #OPSCC #RadiationOncology #MedicalOncology #ENT #NavDx #Naveris

As Pride Month comes to a close, let’s talk about some populations that are too often left out of the HPV-cancer conversation. HPV+ anal cancer incidence is significantly elevated among men who have sex with men (MSM) and people living with HIV. When both factors are present, the incidence is substantially higher. Published cohort studies report incidence ranging from approximately 5-46 per 100,000 person-years for either factor alone, rising to 85-131 per 100,000 among HIV-positive MSM specifically [1,2], compared to roughly 1.5-2 per 100,000 among the general U.S. population.[3]  Equitable, informed cancer care starts with awareness of patient populations at higher than average risk, especially those who face disparities. This Pride Month, we thank all Clinicians who are providing LGBTQ-competent care for patients with HPV-driven cancers. #PrideMonth #HPVAwareness #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #HPV #HPVcancer #AnalCancer #ASCC #ColorectalSurgeon #MedicalOncology #RadiationOncology #NavDx #Naveris 1. Multicenter AIDS Cohort Study (MACS): pmc.ncbi.nlm.nih.gov/article… 2. HPV-Associated Anal Cancer Incidence and Burden Among US Men by Sexual Orientation/HIV Status: pmc.ncbi.nlm.nih.gov/article… 3. SEER Cancer Stat Facts: Anal Cancer seer.cancer.gov/statfacts/ht…

For HPV+ OPSCC patients undergoing CRT, their blood may tell you how treatment is working before imaging can. TTMV®-HPV DNA kinetics during definitive CRT correlate with treatment response:  1. Rapid decline at week 4 may predict mid-treatment tumor volume reduction, and clearance by end-of-treatment is associated with excellent disease-free survival. [1,2]  2. In patients undergoing induction chemotherapy, ctHPVDNA clearance after the first IC cycle predicted final disease control with significantly greater accuracy than PET-CT (61.5% vs. 7.7%, p=0.01). [3]  3. Persistent or rising TTMV-HPV DNA during or after CRT may signal treatment failure, often before imaging confirms it. [1] Want to learn more about these uses? Request a call with a rep who can walk through the many ways NavDx® testing can add valuable insight to your clinical process. bit.ly/4eH3moN #TreatmentMonitoring #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC 1. Routman DM et al. Int J Radiat Oncol Biol Phys. 2022. doi.org/10.1016/j.ijrobp.202….  2. Kim JK et al. Int J Radiat Oncol Biol Phys. 2026. doi.org/10.1016/j.ijrobp.202….  3. Huttinger ZM et al. Oral Oncol. 2025. doi.org/10.1016/j.oraloncolo….

Pro Tip for Patient Navigation: Making Surveillance Convenient One of the most common barriers to consistent post-treatment surveillance? Getting patients to complete imaging or bloodwork. Sometimes they can’t take time off work. Sometimes it’s too far to travel. NavDx® testing can help fill this gap. Testing requires only a standard blood draw, and Naveris® can help arrange convenient phlebotomy options that remove logistical barriers for your patients. We can arrange for a blood draw at their home, workplace, or a walk-in clinic near to them. Results still come directly to you, even if the patient can’t. If surveillance compliance is a challenge in your practice, ask our Clinical Operations Team about Naveris-arranged Phlebotomy, or learn more here. bit.ly/4tl5g1J  #PatientNavigation #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC *NavDx testing is best used as a supplement, not replacement, for traditional surveillance.

May is Asian American and Pacific Islander Heritage Month. Did you know the AAPI community faces significant disparities when it comes to OPSCC? More than 70% of Native Hawaiian and Other Pacific Islander (NHOPI) patients present with advanced stage (III/IV) head & neck cancer (both HPV+ and HPV-), compared to 63.8% of white patients and 60.7% of Asian patients. Five-year overall survival for NHOPI patients is 49.0%, compared to 53.9% for white patients and 57.4% for Asian patients. [1] Disparities in access, screening, and post-treatment follow-up contribute to these outcomes. Recognizing which patients face elevated risk is the first step toward closing the gap. #AAPIHeritageMonth #HealthEquity #CancerDisparities #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC 1. Moon PK et al. JAMA Otolaryngol Head Neck Surg. 2022. doi.org/doi:10.1001/jamaoto.….

Did you know NavDx® testing isn’t reserved for post-treatment surveillance? While post-treatment surveillance is what the NavDx test is best known for, it also has these potential uses in the pre-treatment setting: 1. Confirming HPV+ tumor etiology, especially when tissue-based testing is inconclusive or if FNA is hypo-cellular. 2. Confirming HPV genotype 3. Establishing a baseline that adds prognostic and clinical context to future testing 4. Resolving inconclusive ambiguous clinical and radiological findings related to HPV-driven cancer Want to learn more about these uses? Request a call with a rep who can walk through the many ways NavDx testing can add valuable insight to your clinical process. bit.ly/4dfK47m  #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC

When we talk about post-treatment surveillance, we focus on detection. But what about the time in between surveillance visits? A 2024 patient-reported outcomes study found that negative NavDx® test results significantly reduced anxiety and fear of cancer recurrence in HPV+ OPSCC patients—a measurable improvement in psychological wellbeing. The proportion of patients with clinically elevated distress scores dropped from 36.4% to 18.2% (p=0.031) on the NCCN Distress Thermometer. Anxiety scores improved significantly on the validated Hospital Anxiety and Depression Scale (p=0.037). Importantly, 88.4% of patients reported that testing did not introduce anxiety, and 100% felt some measure of confidence in the assay as a monitoring tool. [1] This Mental Health Awareness Month: surveillance isn’t only about catching recurrence. For many patients, a negative result may be one of the most reassuring things they receive. Hear Providers discuss the positive impact the NavDx test has had on their patients. bit.ly/42Xq84s   #MentalHealthAwarenessMonth #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC  1. Bastien AJ rt al. Oral Oncol. 2024. doi.org/10.1016/j.oraloncolo….

Ten years ago, liquid biopsy in HPV+ cancer was a hypothesis. Today, TTMV®-HPV DNA surveillance has been validated across multiple prospective studies, expert consensus recommendations, and a systematic meta-analysis with pooled sensitivity of 86% and specificity of 96% across 12 studies and more than 1,300 patients. [1] That’s what a decade of focused research looks like. #NationalCancerResearchMonth #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC 1. Campo F et al. J Exp Clin Cancer Res. 2024. doi.org/10.1186/s13046-024-0… .

May is Oncology Nursing Month, and we want to recognize the nurses who are on the front lines of HPV+ cancer care. From coordinating surveillance schedules to preparing patients for what life after treatment looks like, you’re the ones making sure patients don’t fall through the cracks. Thank you for the work you do every day. #OncologyNursingMonth #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC

HPV+ OPSCC carries an excellent prognosis, but recurrence still occurs in 15–25% of patients. When it does, timing matters. Post-treatment NavDx® testing can detect recurrence with a median lead time of 4 months before clinical or imaging-confirmed findings [1], 89% sensitivity and 97% specificity. [2] With an NPV of 98%, a negative result provides meaningful reassurance alongside clinical surveillance. [2] One blood draw. Information that imaging can’t always provide this early. Reassurance your patients find priceless. Learn more about the NavDx test’s performance metrics. bit.ly/4ew5XBL    #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC  1. Chera BS et al. J Clin Oncol. 2020. doi.org/10.1200/JCO.19.02444.   2. Hanna GJ, Roof SA et al. Clin Cancer Res 2023. doi.org/10.1158/1078-0432.CC….

If you're heading to the 2026 ASCRS Annual Meeting, May 9-12 in Tampa, come find us at Booth 912. We’ll be on hand to discuss TTMV®-HPV DNA surveillance with NavDx® testing in HPV+ anal squamous cell carcinoma, including the latest data on early recurrence detection and how NavDx testing integrates into post-treatment care. Stop by if you’re seeing ASCC patients and want to talk through the evidence or clinical workflow. ascrsasm2026.eventscribe.net… #ASCRS2026 #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #HPV #HPVcancer #AnalCancer #ASCC #CancerSurveillance #Oncology #Biotech

Facts to consider about HPV+ head & neck cancer recurrence: 1. Traditional surveillance is inherently limited. The field of view is restricted to local anatomy. Exam accuracy may be reduced due to post-treatment inflammation and fibrosis.  2. ~50% of recurrences occur outside the head and neck.[1] Many present as distant metastases. 3. 75% of patients with recurrence are asymptomatic at detection with the NavDx® test.[2] Facts to consider about the NavDx test: 1. It’s designed to detect a whole-body molecular signal and is not confined by an imaging field, by visual exam, or by palpation. 2. It detects minimal residual and distant metastatic disease. 3. It is not impacted by any post-treatment physical changes. In practice, the NavDx test shifts surveillance from “what can we see” to “what biology is active.” After all, if recurrence can be systemic, your surveillance should be too. bit.ly/3NZ9uh1  #NavDx #Naveris #Oncology #Diagnostics #PrecisionMedicine #HPV #HPVCancer #HeadAndNeckCancer #HNCancer  1. Chatfield-Reed, K., Roche, V. P. & Pan, Q. cfDNA detection for HPV+ squamous cell carcinomas. Oral Oncol. 115, 104958 (2021). 2. Berger, B. M. et al. Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 28, 4292–4301 (2022).

When it comes to HPV+ head & neck cancer, surveillance tools must perform where it matters most: Predicting true recurrence.  The NavDx® test outperforms traditional surveillance methods with ≥95% positive predictive value[1] versus physical exam with endoscopy (0-75%)[2,3] and PET/CT (8-30%).[4,5,6] When false positives result in unnecessary imaging, procedures, and patient anxiety, test accuracy isn’t just academic. It’s clinical strategy.  Learn more about how the NavDx test can complement your surveillance protocol. bit.ly/4t0ewZu #NavDx #Naveris #Oncology #Diagnostics #PrecisionMedicine #HPV #HPVCancer #HeadAndNeckCancer #HNCancer 1. Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res 2023. doi: 10.1158/ 1078-0432.CCR-23-1478.  2. Krabbe, C. A. et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 50, 1940–1947 (2009). 3. Kostakoglu, L. et al. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. The Oncologist 18, 1108– 1117 (2013).  4. Moeller, B. J. et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 2509–2515 (2009). 5. Kao, J. et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 115, 4586– 4594 (2009). 6. Wong, E. T. et al. 18 F-FDG PET/CT for locoregional surveillance following definitive treatment of head and neck cancer: A meta-analysis of reported studies. Head Neck 41, 551–561 (2019).